drugset
drugset / Trial / NCT01140503

A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis

NCT01140503 ↗

Terminated 5 enrolled Stanford University
NaSingle-groupOpen-labelTreatment

Summary

This study is designed to evaluate the safety and efficacy of an oral medicine (called apremilast) for treating skin involvement in patients with the disease dermatomyositis.

Timeline

Start
2010-02
Primary completion
2011-08
Completion
2011-09

Outcome

Outcome not reported

Stopped (Enrollment): “Slow recruitment of participants”

Drugs

EvaluationDrugModalityDoseRoute
Subject Apremilast Small molecule 20 mg Oral

Indications

dermatomyositis